首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Glucagon stimulation test for the diagnosis of GH deficiency in adults.
【24h】

Glucagon stimulation test for the diagnosis of GH deficiency in adults.

机译:胰高血糖素刺激试验用于诊断成人生长激素缺乏症。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The insulin tolerance test (ITT) is considered the test of choice for the diagnosis of GH deficiency (GHD). However, in patients with contraindications to ITT, alternative provocative tests must be used with appropriate cut-offs. The glucagon stimulation test has proved to be a safe, low-cost and effective means of stimulating GH secretion, and therefore can be considered as a suitable alternative to the ITT. We have studied the GH response to the glucagon test in 33 patients with known pituitary disease, 12 males and 21 females, aged between 21 and 60 yr (41.18 +/- 9.47 yr); 5 had isolated GHD and 28 had panhypopituitarism. We also evaluated a control group of 25 individuals, matched for age and sex (8 males and 17 females), aged between 20 and 60 yr (39.28 +/- 12.10 yr). They were selected via the ITT if their peak GH response was > 5.0 ng/ml. GH peak after glucagon was significantly lower in the group of patients compared to the control group (0.49 +/- 0.85 vs 8.69 +/- 5.85 ng/ml, p = 0.0001). Receiver-operating characteristic (ROC) plot analyses of the control and GHD group showed an area under the curve of 0.982 for GH peak response to glucagon. The response value of 3.0 ng/ml showed the best pair of sensitivity (97)/specificity (88), and was chosen as the cut-off defining GHD. After evaluation of positive predictive values (PPV) and negative predictive values (NPV) through simulation of different prevalences of the disease, we concluded that the cut-off point of 3.00 ng/ml maximizes both PPV and NPV (100). In conclusion, we have shown that the glucagon stimulation test has a good performance and great diagnostic accuracy for the diagnosis of GHD.
机译:胰岛素耐量试验 (ITT) 被认为是诊断生长激素缺乏症 (GHD) 的首选试验。然而,对于有 ITT 禁忌证的患者,必须使用具有适当临界值的替代激发试验。胰高血糖素刺激试验已被证明是一种安全、低成本和有效的刺激生长激素分泌的方法,因此可以被认为是 ITT 的合适替代品。我们研究了 33 名已知垂体疾病患者的 GH 对胰高血糖素试验的反应,其中 12 名男性和 21 名女性,年龄在 21 至 60 岁之间(41.18 +/- 9.47 岁);5 例为单纯性 GHD,28 例为全垂体功能减退症。我们还评估了 25 名个体的对照组,年龄和性别匹配(8 名男性和 17 名女性),年龄在 20 至 60 岁(39.28 +/- 12.10 岁)之间。如果他们的峰值 GH 反应> 5.0 ng/ml,则通过 ITT 选择他们。 与对照组相比,患者组胰高血糖素后的 GH 峰值显着降低(0.49 +/- 0.85 vs 8.69 +/- 5.85 ng/ml,p = 0.0001)。对照组和 GHD 组的受试者操作特征 (ROC) 图分析显示,GH 峰值对胰高血糖素的反应曲线下面积为 0.982。3.0 ng/ml 的响应值显示出最佳的灵敏度 (97%)/特异性 (88%),并被选为定义 GHD 的临界值。在通过模拟该疾病的不同患病率评估阳性预测值(PPV)和阴性预测值(NPV)后,我们得出结论,临界点为3。00 ng/ml 可使 PPV 和 NPV 最大化 (100%)。综上所述,胰高血糖素刺激试验对GHD的诊断具有良好的性能和较高的诊断准确性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号